Amyloid-β deposits lead to retinal degeneration in a mouse model of Alzheimer disease

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 11, 2008, Pages 5136-5143

  Ning, Allison ^a   Cui, Jing ^a   To, Eleanor ^a   Ashe, Karen Hsiao ^b   Matsubara, Joanne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIBODY; CHEMOKINE; F4/80 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PRESENILIN 1; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DIFFERENTIATION ANTIGEN; MEMBRANE PROTEIN; MONOCYTE MACROPHAGE DIFFERENTIATION ANTIGEN; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN NERVE CELL; CELL PROLIFERATION; CHOROID CAPILLARY LAYER; COMPARATIVE STUDY; CONTROLLED STUDY; GENE; GROUPS BY AGE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROGLIA; MOUSE; NERVE FIBER; NICK END LABELING; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA; RETINA BIPOLAR GANGLION CELL; RETINA DEGENERATION; RETINA GANGLION CELL; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE; ANIMAL; DISEASE MODEL; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIGENS, DIFFERENTIATION; APOPTOSIS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; RETINA; RETINAL DEGENERATION;

EID: 56149088067     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-1849     Document Type: Article

References (56)

1. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ. Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol. 1987;104(2):113-120. (Pubitemid 17119032)
2. Baker DR, Mendez MF, Townsend JC, Ilsen PF, Bright DC. Optometric management of patients with Alzheimer's disease. J Am Optom Assoc. 1997;68(8):483-494. (Pubitemid 127115536)
3. Tsai CS, Ritch R, Schwartz B, et al. Optic nerve head and nerve fiber layer in Alzheimer's disease. Arch Ophthalmol. 1991;109(2):199-204.
4. Hedges TR 3rd, Perez Galves R, Speigelman D, Barbas NR, Peli E, Yardley CJ. Retinal nerve fiber layer abnormalities in Alzheimer's disease. Acta Ophthalmol Scand. 1996;74(3):271-275.
5. Danesh-Meyer HV, Birch H, Ku JY-F, Carroll S, Gamble G. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology. 2006;67:1852-1854. (Pubitemid 44900767)
6. Iseri PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol. 2006;26(1):18-24. (Pubitemid 44502755)
7. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2007;420(2):97-99. (Pubitemid 46818666)
8. Trick GL, Barris MC, Bickler-Bluth M. Abnormal pattern electroretinograms in patients with senile dementia of the Alzheimer type. Ann Neurol. 1989;26(2):226-231. (Pubitemid 19193091)
9. Katz B, Rimmer S, Iragui V, Katzman R. Abnormal pattern electroretinogram in Alzheimer's disease: evidence for retinal ganglion cell degeneration? Ann Neurol. 1989;26(2):221-225. (Pubitemid 19193090)
10. Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F. Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol. 2001;112(10):1860-1867. (Pubitemid 32831524)
11. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci. 2007;48(5):2285-2289. (Pubitemid 351261307)
12. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med. 1986;315(8):485-487.
13. Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal degeneration in the macula of patients with Alzheimer's disease. Ann N Y Acad Sci. 1991;640:44-46.
14. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4(1):97-100. (Pubitemid 28133087)
15. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102. (Pubitemid 26332733)
16. Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710-713. (Pubitemid 26360645)
17. Westerman MA, Cooper-Blacketer D, Mariash A, et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22(5):1858-1867. (Pubitemid 35386304)
18. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17(6):157-165. (Pubitemid 32409891)
19. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373(6514):523-527.
20. Chishti MA, Strome R, Carlson GA, Westaway D. Syrian hamster prion protein (PrP) is expressed in photoreceptor cells of the adult retina. Neurosci Lett. 1997;234:11-14. (Pubitemid 27435957)
21. Yoshida S, Yoshida A, Ishibashi T, Elner SG, Elner VM. Role of MCP-1 and MIP-1 alpha in retinal neovascularization during post-ischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol. 2003;73:137-144. (Pubitemid 36125684)
22. Ambati J, Anand A, Fernandez S, Sakurai W, Lynn BC, Kuziel WA. An animal model of age-related macular degeneration in senescent Ccl-2 or Ccr-2 deficient mice. Nat Med. 2003;9:1390-1397. (Pubitemid 37466188)
23. Davies MH, Eubanks JP, Powers MR. Microglia and macrophages are increased in response to ischemia-induced retinopathy in the mouse retina. Mol Vis. 2006;12:467-477.
24. Blanks JC, Torigoe Y, Hinton DR, Blanks RHI. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging. 1996;17:377-384. (Pubitemid 26201356)
25. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RHI. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996;17:385-395. (Pubitemid 26200415)
26. Curcio CA, Drucker DN. Retinal ganglion cells in Alzheimer's disease and aging. Ann Neurol. 1993;33:248-257. (Pubitemid 23081155)
27. Vinters HV, Wan ZZ, Secor DL. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol. 1996;6:179-195. (Pubitemid 26160505)
28. Suo Z, Humphrey J, Kundz A, Sethi F. Soluble Alzheimer's beta amyloid constricts the cerebral vasculature in vivo. Neurosci Lett. 1998;257:77-80. (Pubitemid 28552892)
29. Fryer JD, Taylor JW, DeMattos RB, et al. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci. 2003;23:7889-7896.
30. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S. AB1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci. 2000;97:9735-9740. (Pubitemid 30650845)
31. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005-1015. (Pubitemid 44353380)
32. McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol. 2002;8:529-538. (Pubitemid 36104718)
33. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of β amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res. 2004;78:243-256. (Pubitemid 38077231)
34. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:11830-11835.
35. Dentchev T, Milam AH, Lee VMY, Trojanowski JQ, Dunaief JL. amyloid-β is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis. 2003;9:184-190. (Pubitemid 38097585)
36. Green RG, Harlan JB. Histopathologic features. In: Berger JW, Fine SL, Maguire MG, eds. Age-Related Macular Degeneration. St. Louis, MO: Mosby; 1999:81-154.
37. Bressler SB, Maguire MG, Bressler NM, Fine SL. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol. 1990;108:1442-1444.
38. Seth A, Cui J, To E, Kwee M, Matsubara J. Complement associated deposits in the human retina. Invest Ophthalmol Vis Sci. 2008;49(2):743-750.
39. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385-389. (Pubitemid 40530070)
40. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
41. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102:7227-7232.
42. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421. (Pubitemid 40530081)
43. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci U S A. 2006;103:17456-17461.
44. Rogers J, Cooper NR, Webster S, et al. Complement activation by beta amyloid in Alzheimer disease. Proc Nat Acad Sci U S A. 1992;89:10016-10020.
45. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol. 2007;184:69-91.
46. Johnson PT, Brown MN, Pulliam BC, Anderson DH, Johnson LV. Synaptic pathology, altered gene expression, and degeneration in photoreceptors impacted by drusen. Invest Ophthalmol Vis Sci. 2005;46:4788-4795.
47. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
48. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:14682-14687. (Pubitemid 35334544)
49. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest. 2006;116:378-385. (Pubitemid 43228354)
50. Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res. 2008;48(3):339-345. (Pubitemid 351179512)
51. Murisier F, Guichard S, Beermann F. Distinct distal regulatory elements control tyrosinase expression in melanocytes and the retinal pigment epithelium. Dev Biol. 2007;303:838-847. (Pubitemid 46341286)
52. Gupta N, Fong J, Ang LC, Yucel YH. Retinal tau pathology in human glaucomas. Can J Ophthalmol. 2008;43(1):53-60. (Pubitemid 351269569)
53. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43(4):1077-1087
54. McKinnon SJ. Glaucoma: Ocular Alzheimer's disease. Front Biosci. 2003;8:1140-1156
55. Goldblum D, Kipfer-Kauer A, Sarra GM, Wolf S, Frueb BE. Distribution of amyloid precursor protein and amyloid-B immunoreactivity in DBA/2J glaucomatous mouse retinas. Invest Ophthalmol Vis Sci. 2007;48(11):5085-5090. (Pubitemid 351260918)
56. Guo L, Salt TE, Luong V, et al. Targeting amyloid-β in glaucoma treatment. Proc Natl Acad Sci U S A. 2007;104:13444-13449.